NRP1-PDC

1 study on NRP1-PDC curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.

Bottom line: TitrateLab currently curates 1 dated study on NRP1-PDC. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.

NRP1-PDC studies and clinical research

2026-04-21 PubMed · preclinical animal · n preclinical

Novel Peptide-Drug Conjugate Shows Strong Anti-Glioma and Anti-Angiogenesis Effects

This study highlights the significant potential of NRP1-PDC as a dual-action therapeutic strategy for highly aggressive cancers like glioblastoma. By simultaneously targeting tumor cells and their blood supply through…

Research tools

Free, no account — handy when you're working with NRP1-PDC.

Reconstitution calculator Bac water, concentration & insulin-unit math Verify a COA Look up a report number against our corpus

TitrateLab PRO

Unlock the complete evidence trail

Pro members save studies and unlock the full evidence breakdown and vendor lab data.

Complete vendor lab histories
Every linked certificate on file
Batch-level purity and quantity detail
Thousands of community reviews

Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.

$12 monthly or $33 lifetime

Create free account

TitrateLab

You must be 21 or older to enter.

TitrateLab provides research-use information on peptides for adults. Confirm your age to continue.

For research purposes only. Not for human consumption. By entering you agree to our Terms & Privacy.

NRP1-PDC studies and clinical research

Novel Peptide-Drug Conjugate Shows Strong Anti-Glioma and Anti-Angiogenesis Effects

Research tools